BXCL501 given shortly after a car crash to reduce acute stress and later PTSD symptoms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double‑blind, placebo‑controlled Phase 2 trial enrolling about 100 adults who present to the ED within 72 hours of a motor vehicle collision and are expected to be discharged home. Participants receive a first dose in the ED and are discharged with a two‑week supply of BXCL501 (dexmedetomidine HCl sublingual film) or placebo, with serial assessments in the hours, days, and weeks afterward. The primary outcome is reduction in acute stress reaction/acute stress disorder symptoms, with secondary outcomes including neurocognitive function and longer‑term posttraumatic stress symptoms, plus monitoring of safety and adverse events. The design leverages prior safety data for BXCL501 in other disorders but applies the drug acutely after trauma to try to alter early stress responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ≥ 18 years and ≤ 65 years of age
2. Admitted to ED within 72 hours of MVC
3. Anticipated to be discharged home from the ED
4. Stated willingness to comply with all study procedures and availability for the duration of the study
5. Consent to receive unencrypted communications
6. Has a smartphone with continuous service for ≥ 1 year
7. Has a personal email address they regularly access
8. Able to speak and read English
9. Females of childbearing potential (not surgically sterilized (tubal ligation/hysterectomy) or not post-menopausal (no menstrual period for \> 12 months)) must be willing to use a medically acceptable and effective birth control method for 3 months before the study and while participating in the study. Medically acceptable methods of contraception that may be used by the participant include abstinence, birth control pills or patches, birth control implants, diaphragm, intrauterine device (IUD), or condoms

Exclusion Criteria:

1. Substantial comorbid injury (e.g., long bone fracture)
2. People of childbearing potential who are pregnant, breastfeeding, planning to become pregnant, or not using a highly effective form of contraception (e.g., implants, intrauterine devices (IUDs), tubal ligation, hormonal birth control pills, patches, vaginal rings, or injections) during their participation
3. Prisoner status
4. Chronic daily opioid use prior to MVC (\> 20 mg oral daily morphine equivalents)
5. Bipolar disorder, psychotic disorder, active psychosis, suicidal ideation, or homicidal ideation
6. Hospital admission
7. Clinically significant history of cardiac disease including (a) history of syncope or other syncopal attacks; (b) current evidence of orthostatic hypotension (defined as a decrease in systolic BP of 20 mm Hg or decrease in diastolic BP of 10mm Hg within 3 minutes); (c) resting heart rate of \<55 beats per minute; (d) systolic blood pressure \<110mmHg or diastolic BP \<70mmHg; (e) participants with a QTC interval \>440msec (males) or \>460msec (females) not in sinus rhythm; or 1st, 2nd or 3rd degree hearth block; or (f) history of severely impaired ventricular function (ejection fraction \< 30%).
8. Hypomagnesia (\<1.7 mg/dL) or hypokalemia (\< 3.0 mEq/L)
9. Substantial hepatic impairment (e.g. AST or ALT \> 3 times the upper limit of normal or history of cirrhosis).
10. Currently taking the following medications: a) medications for alcoholism (e.g. naltrexone, disulfiram, topiramate, acamprosate); b) psychotropic medications that promote sedation including sedative/hypnotics, barbiturates, antihistamines, sedative antidepressants (e.g. doxepin, mirtazapine, trazodone), and triptans (e.g., sumatriptan); c) alpha-2-adrenergic agonists (clonidine, guanfacine, lofexidine); d) adrenergic agents prescribed for other reasons (prazosin); e) or medications known to cause QT prolongation. (Permitted Concomitant Medications: The concomitant medications allowed in the study include non-sedative antidepressants used to treat PTSD)
11. Hypersensitivity or history of allergic reaction to dexmedetomidine
12. Lacking capacity to provide informed consent (receipt of sedative, hypnotic agent making the patient non-decisional for consent)
13. Any other history or condition that would, in the site investigator's judgement, indicate that the patient would very likely be non-compliant with the study or unsuitable for the study (e.g., might interfere with the study, confound interpretation, or endanger patient)
14. Participation in any other clinical trial of a pharmacological agent within 30 days prior to screening.

Where it's running

• University of Florida College of Medicine - Jacksonville
  Jacksonville, Florida, United States Recruiting
• UVA University Hospital
  Charlottesville, Virginia, United States Recruiting
• Washington University in St. Louis
  St Louis, Missouri, United States Not yet recruiting

Study contacts

• Principal investigator: Samuel McLean, MD — University of North Carollina at Chapel Hill
• Study coordinator: Romina Soudavari, MPH
• Email: romina_soudavari@med.unc.edu
• Phone: 9843195030

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using TNX-102 SL to reduce acute stress reactions after motor vehicle collisions

  This study is testing if a new medication can help people who have just been in a car accident feel less stressed and prevent long-term trauma symptoms.

  Recruiting at 9 sites Phase 2 University of North Carolina, Chapel Hill · Birmingham, Alabama and 8 other locations · NCT06636786

• Anger, Social Thinking, and PTSD in French Veterans

  This study tests whether PTSD in former French military personnel is linked to higher anger through changes in social thinking abilities.

  Recruiting Direction Centrale du Service de Santé des Armées · Draguignan · NCT07851090

• TSND-201 treatment for PTSD in adults

  This study tests two doses of TSND-201 or placebo to see if it helps adults with PTSD.

  Recruiting at 9 sites Phase 3 Transcend Therapeutics · Denver, Colorado and 8 other locations · NCT07836647

• Long-term outcomes after Hyperbaric Oxygen Therapy in veterans with TBI, PCS, or PTSD

  This study tests whether benefits from HBOT persist over time for veterans with brain injury or related conditions.

  Recruiting Phase 2 Summit Hyperbarics and Wellness · Boise, Idaho · NCT07732374

• SEE FAR CBT for Adults With PTSD

  This 12-week, one-on-one SEE FAR CBT program tests a trauma-focused therapy to see if PTSD symptoms improve in adults 18 and older.

  Recruiting Community Stress Prevention Center · Kiryat Shmona · NCT07720674

• Brief SEE FAR CBT: a short, focused therapy for adults with PTSD

  A 6-session Brief SEE FAR CBT treatment is tested against usual dynamic psychotherapy for adults with PTSD to see if it reduces symptoms.

  Recruiting Community Stress Prevention Center · Sha'ar Hanegev · NCT07710573

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.